Skip to main content
Media Coverage

Enveric sells cannabis patents to focus on psilocin candidates [Green Market Report]

By February 23, 2024February 29th, 2024No Comments

Enveric Biosciences (NASDAQ: ENVB) is selling one of its cancer-related patent portfolios for an undisclosed amount. Enveric said it plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin.

Full Article >>